Anhui Anke Biotechnology Group Co Ltd
SZSE:300009

Watchlist Manager
Anhui Anke Biotechnology Group Co Ltd Logo
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Watchlist
Price: 8.24 CNY -0.48% Market Closed
Market Cap: 13.8B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Anhui Anke Biotechnology Group Co Ltd stock under the Base Case scenario is 8.62 CNY. Compared to the current market price of 8.24 CNY, Anhui Anke Biotechnology Group Co Ltd is Undervalued by 4%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
8.62 CNY
Undervaluation 4%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.5
P/S
P/S
Price to Sales
5.5
vs History
84
vs Industry
59
Median 3Y
6.1
Median 5Y
6.9
Industry
6.7
Forward
4
More Details
19.7
P/E
P/E
Price to Earnings
19.7
vs History
77
vs Industry
8
Median 3Y
21.2
Median 5Y
38.7
Industry
21.9
Forward
13.8
More Details
19
P/OCF
P/OCF
Price to OCF
19
vs History
80
vs Industry
9
Median 3Y
20.4
Median 5Y
23.5
Industry
19.2
More Details
21.5
P/FCFE
P/FCFE
Price to FCFE
21.5
vs History
90
vs Industry
8
Median 3Y
30.2
Median 5Y
39.4
Industry
22.5
More Details
3.3
P/B
P/B
Price to Book Value
3.3
vs History
95
vs Industry
26
Median 3Y
4.6
Median 5Y
5.2
Industry
2.4
More Details
4.9
EV/S
EV/S
Enterprise Value to Sales
4.9
vs History
87
vs Industry
52
Median 3Y
5.7
Median 5Y
6.3
Industry
7.1
Forward
3.6
More Details
6.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.5
vs History
85
vs Industry
50
Median 3Y
7.4
Median 5Y
8.3
Industry
9
More Details
16.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
16.1
vs History
80
vs Industry
9
Median 3Y
17.4
Median 5Y
25.8
Industry
3.7
Forward
9.1
More Details
16.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
16.1
vs History
80
vs Industry
9
Median 3Y
17.4
Median 5Y
25.8
Industry
3.4
Forward
10.6
More Details
17.1
EV/OCF
EV/OCF
Enterprise Value to OCF
17.1
vs History
80
vs Industry
10
Median 3Y
18.7
Median 5Y
21.7
Industry
4.3
More Details
19.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
19.3
vs History
93
vs Industry
7
Median 3Y
27.7
Median 5Y
36.5
Industry
3.4
More Details
3.5
EV/IC
EV/IC
Enterprise Value to IC
3.5
vs History
93
vs Industry
35
Median 3Y
4.7
Median 5Y
5.3
Industry
4.5
More Details

Multiples Across Competitors

Competitors Multiples
Anhui Anke Biotechnology Group Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
13.8B CNY 5.5 19.7 16.1 16.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 349 427.2 -168 010.6 -204 018.4 -201 690.3
US
Abbvie Inc
NYSE:ABBV
325.9B USD 5.8 76.9 15.3 23.1
US
Amgen Inc
NASDAQ:AMGN
143B USD 4.2 24.1 13.3 21.9
US
Gilead Sciences Inc
NASDAQ:GILD
120.7B USD 4.2 20.2 8.9 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
109.2B USD 9.8 -110.4 23.4 24.5
US
Epizyme Inc
F:EPE
94.1B EUR 1 992.9 -508.5 -553.8 -539
AU
CSL Ltd
ASX:CSL
115.9B AUD 4.9 27 16.7 20.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
57.1B USD 4.1 12.7 11.3 12.7
US
Seagen Inc
F:SGT
39.3B EUR 19.2 -58.9 -63.4 -57.2
NL
argenx SE
XBRU:ARGX
30.3B EUR 15.5 40.8 -2 304.7 -1 545.2
P/E Multiple
Earnings Growth PEG
CN
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Average P/E: 31.6
19.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -168 010.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
76.9
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.1
44%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
20.2
187%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -110.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -508.5 N/A N/A
AU
CSL Ltd
ASX:CSL
27
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
10%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.9 N/A N/A
NL
argenx SE
XBRU:ARGX
40.8
28%
1.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Average EV/EBITDA: 15
16.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -204 018.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.3
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
8.9
7%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
18%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -553.8 N/A N/A
AU
CSL Ltd
ASX:CSL
16.7
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.3
14%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.4 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 304.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Average EV/EBIT: 18.8
16.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 690.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
21.9
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
11%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -539 N/A N/A
AU
CSL Ltd
ASX:CSL
20.9
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
13%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.2 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 545.2 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.